Associations Between Obesity and the Effectiveness of Anti–Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis

High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis

(2018) S. Kurnool et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study

(2018) Camilla B. Jensen et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease—A Cohort Study

(2018) Kenneth Grønkjær Madsen et al.   INFLAMMATORY BOWEL DISEASES

Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016

(2018) Craig M. Hales et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn’s Disease

(2018) Ziad Bakouny et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis

(2018) Runsheng Wang et al.   JOURNAL OF RHEUMATOLOGY

Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis

(2018) Siddharth Singh et al.   PLoS One

Review article: the relationship between obesity, bariatric surgery, and inflammatory bowel disease

(2018) Fiorella Cañete et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases

(2018) Nghia H. Nguyen et al.   Clinical Gastroenterology and Hepatology

Adalimumab and Certolizumab Pegol for the Treatment of Crohn's Disease: Does BMI Make a Difference?

(2018) John M. Moore et al.   GASTROENTEROLOGY

Patients with Crohnʼs Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab

(2017) Loic Guerbau et al.   INFLAMMATORY BOWEL DISEASES

Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease

(2017) Amy L. Lightner et al.   JOURNAL OF PEDIATRIC SURGERY

Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab

(2017) Franco Scaldaferri et al.   PLoS One

Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience

(2016) T. Billiet et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Comparative Effectiveness and Safety of Anti–Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn’s Disease

(2016) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels

(2016) Ashley Bond et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Comparative Effectiveness of Infliximab and Adalimumab in Crohnʼs Disease and Ulcerative Colitis

(2016) Ashwin N. Ananthakrishnan et al.   INFLAMMATORY BOWEL DISEASES

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

(2016) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn’s Disease

(2016) Peter Brown et al.   Journal of Crohns & Colitis

Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes

(2016) Siddharth Singh et al.   Nature Reviews Gastroenterology & Hepatology

Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Disease

(2015) Jennifer L. Seminerio et al.   INFLAMMATORY BOWEL DISEASES

Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohnʼs Disease

(2015) Patricia L. Pringle et al.   INFLAMMATORY BOWEL DISEASES

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

(2015) Taku Kobayashi et al.   JOURNAL OF GASTROENTEROLOGY

Sa1925 Does Obesity Impact Treatment Efficacy of Adalimumab and Certolizumab Pegol in Crohn's Disease?

(2015) Benjamin Click et al.   GASTROENTEROLOGY

Sa1880 Increased Body Mass Index Predicts Need for Surgery in Crohn's Disease Patients Treated With Certolizumab

(2015) Melissa H. Rosen et al.   GASTROENTEROLOGY

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

(2014) R. W. Stidham et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

The effect of body weight on the severity and clinical course of ulcerative colitis

(2014) Denia Stabroth-Akil et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease?

(2013) Mahesh Bhalme et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease

(2013) Jason W. Harper et al.   INFLAMMATORY BOWEL DISEASES

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

(2012) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adipose Tissue and Inflammatory Bowel Disease Pathogenesis

(2012) Christopher Fink et al.   INFLAMMATORY BOWEL DISEASES

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

W1106 Increased BMI Is Not Associated with Dose Escalation or Failure of Adalimumab Therapy in Crohn's Disease

(2009) Bashar Qumseya et al.   GASTROENTEROLOGY

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

(2009) William J. Sandborn et al.   GASTROENTEROLOGY